High mobility box protein-1 may be a new biomarker in active interstitial lung disease of systemic sclerosis
Derya Yildirim 1 * , Gizem Tugce Alp 2 , Hikmet Kilicarslan 2 , Ibrahim Vasi 1 , Hamit Kucuk 1
More Detail
1 Gazi University Faculty of Medicine, Department of Rheumatology, Ankara, TÜRKİYE2 Gazi University Faculty of Medicine Department of Internal Medicine, Ankara, TÜRKİYE* Corresponding Author


Introduction: To investigate the significance of high mobility group box 1 (HMGB1) levels as both an immune and inflammatory mediator in systemic sclerosis (SSC) patients with interstitial lung disease (SSC-ILD) and whether HMGB1 levels could be a biomarker for progression and disease activity.
Materials & methods: Our study included 27 patients diagnosed with SSC according to the 2013 ACR/EULAR classification criteria, along with 12 healthy controls (HC). Among the patients with a diagnosis of SSC, they were further categorized into two groups based on the presence of ILD with 19 patients having lung involvement and eight patients without. In ILD-positive group, the activity of the involvement was assessed using the simple Goh algorithm. Serum levels of HMGB1 were evaluated in all groups using ELISA method.
Results: Significantly higher serum HMGB1 levels were found in patients with SSC-ILD active disease when compared to those with inactive ILD involvement and HC (14.01 mg/dl vs. 7.87 mg/dl and 8.04 mg/dl).
Conclusions: Serum HMGB1 levels reflect the disease activity in SSC-ILD. HMGB1 could be used for a potential biomarker for detecting active lung disease.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Research Article

J CLIN EXP INVEST, 2024, Volume 15, Issue 1, Article No: em00833


Publication date: 14 Mar 2024

Article Views: 164

Article Downloads: 96

Open Access References How to cite this article